SkyView Investment Advisors’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

SkyView Investment Advisors’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-71,773	Closed	-$728K	–	888
2023 Q1	$728K	Hold	71,773	–	–	0.17%	162
2022 Q4	$717K	Hold	71,773	–	–	0.22%	160
2022 Q3	$719K	Hold	71,773	–	–	0.21%	163
2022 Q2	$710K	Hold	71,773	–	–	0.19%	179
2022 Q1	$706K	Hold	71,773	–	–	0.17%	183
2021 Q4	$701K	Buy	71,773 +5,310	+8%	+$52K	0.16%	167
2021 Q3	$650K	Buy	+66,463	New	+$648K	0.18%	144

SkyView Investment Advisors's EUCR Position: Q2 2023 in Review

SkyView Investment Advisors sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q2 2023, closing a stake of 71,773 shares — an estimated $728K sold.

SkyView Investment Advisors first reported a position in EUCR in Q3 2021 and held it in 7 quarters. The position peaked at $728K in Q1 2023. 0 funds tracked by Wall St. Rank hold EUCR as of Q2 2023.

SkyView Investment Advisors reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q2 2023 after selling out during the quarter.
SkyView Investment Advisors sold 71,773 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q2 2023, an estimated $728K.
SkyView Investment Advisors first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q3 2021 and held it in 7 quarters.
SkyView Investment Advisors's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $728K in Q1 2023.
0 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q2 2023.

Based on SkyView Investment Advisors's 13F filing for Q2 2023, filed 15 Aug 2023.